Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, methylnaltrexone bromide (Relistor®) cannot be endorsed for use within NHS Wales for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients aged 18 years and older. |
||
|
||
Medicine details |
||
| Medicine name | methylnaltrexone bromide (Relistor®) | |
| Formulation | 12 mg/0.6 ml solution for injection | |
| Reference number | 2798 | |
| Indication | In the absence of a submission from the holder of the marketing authorisation, methylnaltrexone bromide (Relistor®) cannot be endorsed for use within NHS Wales for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients aged 18 years and older. |
|
| Company | TMC Pharma Services Ltd | |
| BNF chapter | Gastro-intestinal system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 09/10/2015 | |
| Date of issue | 13/10/2015 | |